Sun, Mar 1, 2015, 10:15 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • bearofbleecker bearofbleecker Apr 5, 2013 4:29 PM Flag

    Note on International MM Workshop

    Looking at the press release in the Onyx website, I see that the only "new data" to be presented in Kyota are for trials of opromozib in hematological malignancies. (This presentation has already taken place, I think. We might recall that there were a lot of hints in the last CC that they place a lot of importance on this oral proteasome inhibitor.) For Kyrpolis, their major presentation is a study of Kyrpolis in combination with Revlimid and low-dose dexamethasone in high-risk smoldering myeloma in the elderly. This is moving Kyrpolis way up in the order of battle. I imagine that these patients, being elderly, are not candidates for stem cell transplants and therefore the various treatment cycles (Velcade, chemotherapy, etc.) which precede it. The theory here, I gather, would be to throw the three least noxious drugs at them in combination to see if this will slow their progression to fullblown MM.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.